Day: September 27, 2023

VS Media Limited Announces Pricing of Initial Public Offering

HONG KONG, Sept. 27, 2023 (GLOBE NEWSWIRE) — VS Media Holdings Limited (NASDAQ: VSME) (“VS Media,” or the “Company”) today announced the pricing of its initial public offering of 2,000,000 Class A ordinary shares at a price to the public of $5.00 per share for a total of $10,000,000 of gross proceeds to the Company (the “Offering”), before deducting underwriting discounts, commissions, and other Offering expenses. The shares are expected to begin trading on The Nasdaq Capital Market on September 27, 2023, under the ticker symbol “VSME.” The Offering is expected to close on September 29, 2023, subject to the satisfaction of customary closing conditions. Univest Securities, LLC is acting as the underwriter for the Offering. A registration statement on Form F-1, as amended (File No. 333-273914), relating to...

Continue reading

Paramount Gold Nevada Provides Details of Its Upcoming AGM

WINNEMUCCA, Nev., Sept. 27, 2023 (GLOBE NEWSWIRE) — Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) is pleased to announce that its Annual General Meeting (“AGM” or the “meeting”) of the stockholders will be held on December 12, 2023 at 11:00 AM eastern standard time. The meeting will be held virtually over the Internet. Proxy materials will be available on or about October 30th, the mail date, at www.edocumentview.com/PZG and on the Company’s website. The Board of Directors has fixed the close of business on Monday, October 16, 2023 as the record date for the determination of the stockholders entitled to notice of, and to vote at, the AGM. The Company also advised that it filed its annual audited financial statements for the fiscal year ended June 30, 2023 on Form 10-K with the Securities and Exchange...

Continue reading

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R mutations in KRAS As of the April 25, 2023 data cut-off date, among the 22 evaluable patients, preliminary data from the trial suggest that those with greater than median T cell response had not reached median Relapse-Free Survival compared to median RFS of 3.91 months for patients with less than median T cell response Updated data demonstrated 86% reduction in risk of progression or death in patients with large T cell responses induced by ELI-002 2P in the phase 1 study Elicio plans to initiate a randomized phase 2 study early in 2024 for ELI-002 7P BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline...

Continue reading

Purpose Investments Inc. Announces 2023 Third Quarter Distributions for Purpose Specialty Lending Trust

TORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Purpose Investments Inc. is pleased to announce the 2023 third-quarter distributions for Purpose Specialty Lending Trust.   TickerSymbol Distributionpershare/unit ExDistributionDate RecordDate PayableDate Purpose Specialty Lending Trust – Class A Unlisted $ 0.1190 09/28/2023 09/29/2023 10/23/2023 Purpose Specialty Lending Trust – Class F Unlisted $ 0.1230 09/28/2023 09/29/2023 10/23/2023 Purpose Specialty Lending Trust – Class U Unlisted US$ 0.1570 09/28/2023 09/29/2023 10/23/2023 Purpose Specialty Lending Trust – Class A1, Series 2 Unlisted $ 0.1380 09/28/2023 09/29/2023 10/23/2023 Purpose Specialty Lending Trust – Class F, Series 3 Unlisted $ 0.1425 09/28/2023 09/29/2023 10/23/2023 About Purpose Investments Inc. Purpose Investments Inc. is an asset management company with...

Continue reading

Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date

VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce expected admission of its common shares to begin trading on the Access Segment of the AQSE Growth Market in the UK is expected to take place on October 10th, 2023. The AQSE Growth Market is a multilateral trading facility operated by Aquis Stock Exchange. A copy of the application announcement can be accessed at the following link: https://aqx-web-prod-s3-public-read.s3.eu-west-2.amazonaws.com/20230926_Application_Announcement_1_5533c9b702.pdf Management Commentary: Josh...

Continue reading

Modulex Modular Buildings Plc Announces Submission of Registration Statement on Form S-4 Related to Proposed Merger with PHP Ventures Acquisition Corp.

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — Modulex Modular Buildings Plc (“Modulex”), a UK-based, globally focused “ConstrucTech” manufacturer of modular buildings today announced that it has filed a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) on September 27, 2023 relating to its previously announced proposed business combination (the “Business Combination”) with PHP Ventures Acquisition Corp. (NASDAQ: PPHP) a publicly traded special purpose acquisition company (“PHP”). The Registration Statement contains a preliminary proxy statement/prospectus in connection with the Business Combination. Modulex is a cutting-edge, UK-headquartered “ConstrucTech” company offering Carbon Net Zero certified, advanced 3D volumetric steel modular buildings embedded with...

Continue reading

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023. The company plans to present preliminary anti-tumor activity, safety, pharmacokinetic and pharmacodynamic data from its Phase 1/2 clinical trial for XTX202, a tumor-activated, engineered, beta-gamma biased IL-2, as well as preclinical data for XTX301, a tumor-activated, engineered IL-12. Poster presentation details: Title: Phase 1/2 First-in-Human Study of XTX202, a Masked, Tumor-Activated IL-2βγ, in Patients with Advanced Solid...

Continue reading

Cielo Announces Fiscal Q1 2024 Financial Results

CALGARY, Alberta, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cielo Waste Solutions Corp. (TSXV: CMC; OTCQB: CWSFF) (“Cielo” or the “Company”), a waste‐to‐fuel company, today announced its financial results for the three months ended July 31, 2023 and 2022. Copies of the unaudited interim financial statements and related management’s discussion and analysis can be found on the Company’s issuer profile at www.sedarplus.ca. All financial information in this news release is reported in Canadian dollars, unless otherwise indicated. Q1 2024 HIGHLIGHTS During, and subsequent to the quarter, Cielo achieved the following goals: Obtained a $5 million mortgage loan facility to support ongoing operations (initially drawing down $2 million) Executed agreements to terminate MOUs with Renewable U, allowing for repayment of fees in whole or...

Continue reading

AIP Realty Trust Announces Suspension of Third Quarter Distribution and Provides Business Update

VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — AIP Realty Trust (the “Trust” or “AIP”) (TSXV: AIP.U) today announced that its Board of Trustees (the “Board”) has suspended the cash distribution for the third quarter ending September 30, 2023 in the amount of $0.02 per unit. All dollar amounts are stated in U.S. dollars. After careful consideration of the Trust’s financial resources, and while the presently owned Eagle Court facility in Lewisville, TX remains fully leased and occupied and is performing in accordance with pro forma expectations, the Board made the decision to sustain the revision to its distribution policy in order to preserve working capital and maintain financial flexibility. The Board believes the decision supports the Trust’s priority of preserving capital needed as it seeks the means to accomplish...

Continue reading

Mobiv Acquisition Corp Provides Update on Planned Business Combination with SRIVARU

Newark, Delaware, Sept. 27, 2023 (GLOBE NEWSWIRE) — Mobiv Acquisition Corp (Nasdaq: MOBVU, MOBV, MOBVW) (the “Company”), a special purpose acquisition company, announces that it has filed its Definitive Proxy Statement in connection with the planned business combination with SRIVARU Holding Limited (“SRIVARU”), a commercial-stage provider of premium electric motorcycles.  The Company also reports it has entered into a Lock-Up Waiver, effective September 29, 2023, whereby the underwriter of the Company’s initial public offering agreed to waive certain lock-up restrictions applicable to up to 100,000 shares of Class B common stock held by the Mobiv Pte. Ltd., in connection with compensation to be paid in connection with the closing of the planned business combination.   Peter Bilitsch, CEO of Mobiv, stated, “We are making steady...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.